Merck Serono backs Oral infertility treatment spin-off TocopheRx
This article was originally published in Scrip
Executive Summary
A new company has been launched in Boston to develop oral follicle-stimulating hormone (FSH) agonists to treat fertility. Named TocopheRx, it is the eight start-up to be launched under a fostering program set up by Merck Serono last year when it announced the closure of its Swiss headquarters in Geneva and consolidation of central operations with parent company Merck KGaA's HQ in Darmstadt, Germany.